SCHEMBL7433773

SCHEMBL7433773

CCOc1ccc(C(C)=O)c([N+](=O)[O-])c1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.46
TSHR P16473 2/20 0.43
CYP3A4 P08684 1/20 0.43
POLB P06746 3/20 0.42
KDM4E B2RXH2 2/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
CREBBP Q92793 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28059236 0.80 MAPT (0.45) TSHRCYP3A4POLBKDM4ECTDSP1
SCHEMBL10908860 0.78 POLB (0.47) TSHRCYP3A4POLBKDM4EL3MBTL1
SCHEMBL18073577 0.78 PKM (0.48) PKMTSHRCYP3A4POLBKDM4E
SCHEMBL28114768 0.78 ALDH1A1 (0.53) PKMTSHRPOLBKDM4ECTDSP1
SCHEMBL30735954 0.77 PKM (0.47) PKMTSHRCYP3A4POLBKDM4E
SCHEMBL6403079 0.76 ALDH1A1 (0.44) PKMTSHRPOLBKDM4ECTDSP1
SCHEMBL621983 0.76 PKM (0.69) PKMTSHRPOLBKDM4ECTDSP1
SCHEMBL30105934 0.76 PKM (0.69) PKMTSHRPOLBKDM4ECTDSP1
SCHEMBL10958150 0.76 MEN1 (0.46) PKMCYP3A4POLBKDM4ECTDSP1
SCHEMBL10130531 0.75 KMT2A (0.38) PKMPOLBKDM4ECTDSP1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & C.A., S.A. (PT) 2002-03-28 US disclosed
EP-1167341-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them Portela & Ca., S.A. (PT) 2002-01-02 EP disclosed
WO-2001098250-A1 SUBSTITUTED NITRATED CATECHOLS, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PORTELA & CA SA (PT) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them SLC6A2, COMT, SLC6A3 PKM 1192/4885TSHR 3223/4885CYP3A4 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.